[Tocilizumab in COVID-19 patients]
Colaci C, Alfie V, Augustovski F, García Martí S, Bardach A, Ciapponi A, Alcaraz A, Pichon-Riviere A.
Record ID 32018002315
Spanish
Original Title:
Tocilizumab en pacientes con COVID-19
Authors' recommendations:
Moderate-quality evidence suggests that using tocilizumab as an add-on to standard therapies, versus not using it, reduces mortality in patients with severe disease and/or in critical condition due to COVID-19, with no higher risk for adverse effects.
Details
Project Status:
Completed
Year Published:
2021
URL for published report:
https://www.iecs.org.ar/publicacion/?id=20595
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Argentina
MeSH Terms
- COVID-19
- SARS-CoV-2
- Coronavirus Infections
- Antibodies, Monoclonal, Humanized
Contact
Organisation Name:
Institute for Clinical Effectiveness and Health Policy
Contact Address:
Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name:
info@iecs.org.ar
Contact Email:
info@iecs.org.ar
Copyright:
Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.